zanzalintinib (XL092) - Exelixis
Yervoy (ipilimumab) - BMS
Tukysa (tucatinib) - Pfizer
Enhertu (fam-trastuzumab deruxtecan-nxki) - Daiichi Sankyo, AstraZeneca
Erbitux (cetuximab) - Eli Lilly
Tecentriq (atezolizumab) - Roche
Braftovi (encorafenib) - Pfizer
Opdivo (nivolumab) - Ono Pharmaceutical, BMS
Keytruda (pembrolizumab) - Merck (MSD)
http://www.ncbi.nlm.nih.gov/pubmed/42744133
 
Alireza Tojjari; Anwaar Saeed; Shahd Alkhazna; Shamimeh Pourbahrighesmat
 
Sep 16, 2026
 
Prev Next